ADI is disappointed and concerned to learn that France’s Ministry of Health and Solidarity has announced its decision to discontinue reimbursement of four Alzheimer drugs.
This has come as a blow just after the anniversary of the first year of WHO’s Global Action plan on dementia and as ADI is calling for governments to fund further research and innovation in post diagnostic support and care for people living with dementia.
Serge Gauthier, MD, Chair of ADI’s Medical and Scientific Advisory Panel (MSAP), said: “Anti-dementia drugs are an important component of disease management, in many cases temporarily alleviating symptoms or slowing progression of the condition. Ceasing reimbursement will mean that families will need to shoulder the burden of cost themselves”.
ADI is calling for equitable and fair access to anti-dementia drugs. Alongside our MSAP, a global committee of dementia experts, ADI announces that we will apply to register anti-dementia drugs onto the WHO Model List of Essential Medicines. Working alongside research institutions, this process will be led by MSAP and completed by 2020.
Paola Barbarino, CEO of Alzheimer’s Disease International said: “We will insist for these drugs to be made available to everyone. We hope one day there will be more treatments and urge governments to be prepared so that the public will have access to those.”
Helping people with dementia to live well requires a multi-faceted approach, and access to anti-dementia drugs is an important component.